Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2012

View Archived Issues

First clinical data disclosed on new beta-secretase 1 inhibitor for Alzheimer's disease

Researchers at Boehringer Ingelheim patent new CXCR2 receptor antagonists

Novel protein kinase inhibitors synthesized at Bayer Schering Pharma

Novel data disclosed on Esteve drugs for pain

Epizyme scientists disclose new DOT1-like protein inhibitors

New GlyT1 inhibitors presented

Novel neprilysin inhibitors discovered at Theravance

Taisho Pharmaceutical develops new orexin receptor antagonists

Abbott designs new antiviral agents

Amicus and GSK expand collaboration

Agios Pharmaceuticals patents novel PKM2 activators

Convergence Pharmaceuticals plans phase change for CNV-2197944

Novel product reduces accumulation of oligomeric beta-amyloid in brain

Chugai submits NDA for ibandronate sodium hydrate

Dosing begins in BB3 acute myocardial infarction study

AMAG Pharmaceuticals reports preliminary data from IDA-301 trial

First clinical trials assess TOL-101 for preventing kidney transplant rejection

Novavax and PATH partner to develop RSV vaccine for maternal immunization

Alexza reports on Adasuve MAA

Pluristem engages CPC for phase II trial of PLX-PAD

Sanofi enters collaboration with Brigham and Women's Hospital

Infinity Pharmaceuticals regains rights to PI3K, FAAH and early discovery programs

EMA to review MAA for bazedoxifene/conjugated estrogens

Royal Melbourne Institute of Technology to research use of BioDiem's LAIV for noninfluenza vaccines

Phase III trial of rebamipide ophthalmic suspension begins

New S100-A4-neutralizing antibody is a potential therapy and biomarker for cancer

Aeras and IAVI expand vaccine research partnership

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...